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Abstract 
From October 30–November 1, 2015, the 7th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. 
Seventy doctoral students and postdocs from over 25 different groups working in German and Swiss University 
Hospitals or Research Institutes attended the meeting to discuss their latest experiments and findings in the fields 
of neuroimmunology, neurodegeneration and neurovascular research. This meeting report summarizes the many 
diverse presentations and the new preclinical to clinical neurology research data that were shared by the participants 
at the meeting.
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The meeting was regarded as a very well organized plat-
form to support research of young investigators in Ger-
many and all participants enjoyed the stimulating envi-
ronment for lively in-depth discussions.
According to the major aim of the Association for the 
Advancement of Young Academics in Neurology (Verein 
zur Förderung des Wissenschaftlichen Nachwuchses in 
der Neurologie, NEUROWIND e.V.) to support younger 
researchers in Germany the 5th NEUROWIND YOUNG 
SCIENTIST AWARD for experimental neurology was 
awarded to Julia Bruttger (Group of Ari Waisman, Insti-
tute of Molecular Medicine, Johannes Gutenberg Uni-
versity Mainz, Germany) and Daniel von Bornstädt 
(Department of Neurology, Charité Berlin, Germany, 
Chair: Mathias Endres). Julia’s successful project was 
published in Immunity entitled “Genetic cell ablation 
reveals clusters of local self-renewing microglia in the 
mammalian central nervous system”. This outstand-
ing paper deals with microglia repopulation in the adult 
CNS, relying on CNS-resident cells, independent from 
bone-marrow-derived precursors. Daniel’s work enti-
tled “Supply–demand mismatch transients in susceptible 
peri-infarct hot zones explain the origins of spreading 
injury depolarizations” was published in Neuron. This 
outstanding work shows that somatosensory activation 
of peri-infarct cortex triggers peri-infarct depolarization 
when the activated cortex is within a critical range of 
ischemia. Both awards were endowed with 20,000 Euro 
sponsored by Merck Serono GmbH, Darmstadt, Ger-
many (unrestricted educational grant).
This year’s keynote lecture was given by Joseph Classen, 
Head of the Department of Neurology at the University 
Hospital Leipzig. Dr. Classen highlighted the potential of 
repetitive transcranial magnetic stimulation or constant 
transcranial direct current stimulation in neuro-psychi-
atric diseases.
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Summary of the scientific presentations to the 
NEUROWIND e.V. meeting 2015
Lars Tönges (Bochum) reported on novel therapeutic 
targets for neuroprotection in Parkinson’s disease. Rho 
kinase (Rock) was identified as relevant mediator of neu-
rodegeneration but also axonal regneration in the optic 
nerve crush model. This concept was transferred into the 
Parkinson’s disease model of MPTP mediated complex I 
inhibition and 6-OH dopamine lesion in the stereotactic 
striatal lesion model. Here, inhibition of Rock by Fasudil 
or application of AAV shRock2 vectors promoted recov-
ery. Since Rock is expressed both in neuronal cells and in 
glial cells, the relevant cellular target of ROCK inhibition 
remains to be determined in the CNS.
Aiden Haghikia (Bochum) presented data on the mod-
ulation of the immune response by short and long chain 
fatty acids. While long chain fatty acids (e.g. laurate) pro-
moted the generation of Th17 cells in the small intesti-
nal lamina propria, short chain fatty acids enhanced the 
development of Foxp3 regulatory T cells (Tregs). Under 
physiologic conditions, the abundance of these fatty acid 
species was determined by certain taxa of the gut micro-
biome. Since dietary administration of these compounds 
aggravated or reduced EAE, respectively, this observa-
tion might bear some therapeutic potential, in particular 
because human T cells can be modulated accordingly by 
dietary intake of short chain fatty acids (e.g. propionate).
Kathrin Doppler (Würzburg) demonstrated that a 
subset of chronic inflammatory demyelinating poly-
neuropathy (CIDP) patients (about 5  %) harbored anti-
contactin-1 antibodies against a protein expressed at the 
node of Ranvier. She was able to show that these antibod-
ies (frequently of the subtype IgG4) were able to bind 
complement at the site of their binding on teased sci-
atic nerve preparations. Interestingly, the subset of anti-
contactin-1 positive CIDP patients appeared to exhibit 
a distinct clinical phenotype with a relapsing remitting 
form of CIDP following an initial episode of “Guillain 
Barré like-syndrome”. Some patients displayed a tremor. 
In sural nerve biopsy, axonal loss was detected. Most 
CIDP patients with anti-contactin-1 serum antibodies 
responded well to rituxan.
Holger Haselmann (Jena) presented novel data on the 
functional role of anti-α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor antibodies on 
the AMPA receptor. Anti-AMPA receptor antibodies can 
occur as paraneoplastic phenomenon in association with 
tumors (64 %) and are able to cause limbic encephalitis. 
They bind the GluR2 subunit and impair the synaptic 
transmission and recovery after desensitization of the 
AMPA receptor in dissociated hippocampal cells. This 
was tested by single synapse iontophoretic glutamate 
patch clamp techniques analyzing evoked fast excitatory 
postsynaptic currents (eEPSC) in the presence or absence 
of anti-AMPA receptor antibodies. Together with the 
decrease of mEPSC amplitude and frequency in the pres-
ence of anti-GluR2 this was interpreted as loss of active 
receptors in the synapse.
Sarah Glumm (Münster) introduced a novel com-
pound, WMS14–10, for the blockade of N-methyl-d-as-
partic acid (NMDA) receptors. Similar to Ifenprodil, 
WMS14–10 binds to the 2B subunit of the NMDA recep-
tor, but WMS is more selective. WMS14–10 was used 
in a prophylactic and therapeutic treatment regimen 
in experimental autoimmune encephalomyelitis (EAE) 
and was capable to significantly reduce the disease bur-
den. Notably, WMS may directly act on microglia, which 
express GluN2B and down-regulate CD40, CD86 and 
MHCII upon exposure to WMS14–10.
Kai Diederich (Münster) shared his results on the treat-
ment of mice with anti-leucine rich repeat and immu-
noglobin-like domain-containing protein (Lingo)-1 after 
stroke. The rationale for the use of anti-Lingo-1 in stroke 
is the observation that anti-Lingo-1 might improve the 
survival of neuronal and glial precursor cells that can 
be found in the border areas of a stroke lesion and thus 
promote regeneration. This idea was tested in pulse-
chase experiments to label proliferating cells distinguish-
ing cells that started proliferation before stroke (and 
would therefore represent the homeostatic rate of pro-
liferating cells) and after stroke to visualize those cells 
that responded to the lesion. Anti-Lingo-1 treatment 
improved the survival of neuronal cells that started pro-
liferation early post stroke. Notably, the administration of 
anti-Lingo-1 to mice after stroke was associated with an 
improved functional outcome of these mice in the tape 
removal test.
Gemma Llovera (Munich) reported on an alterna-
tive route of cell recruitment into an ischemic lesion. 
By using a photo-activatable green fluorescent protein 
mouse, she could show that immune cells that were acti-
vated by blue light irradiation with a probe in the cho-
roid plexus were recruited to a distant ischemic lesion. 
Within the ischemic lesion, a number of chemokines 
including chemokine (C–C Motif ) ligand (CCL) 2, 7, and 
12 were found to be up-regulated and it is possible that 
in particular microglia that highly express CCL2 after 
stroke are important to attract immune cells including T 
cells from the ipsilateral choroid plexus. At this point, it 
is unclear how T cells recruited from the choroid plexus 
differ from T cells that are recruited through the blood 
brain barrier directly at the site of ischemia.
Nicolas Page (Geneva) presented his results on a novel 
mouse model of CD8 T cell driven auto-immunopathol-
ogy in the central nervous system (CNS). In his model, 
the ODC-OVA mouse which expresses ovalbumin (Ova) 
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in oligodendrocytes under the control of the MBP pro-
moter was seeded with OT-1 cells and subsequently 
infected with either Lymphocytic choriomeningitis 
(LCMV)-OVA or Listeria monocytogenes (Lm)-OVA. 
After clearance of the infectious agent, LCMV-OVA 
infected but not Lm-OVA infected mice developed CNS 
pathology while OT-1 cells were identified in the CNS 
in both cases. By differential gene expression profiling 
of these OT-1 cells, highly interesting novel genes were 
identified that are now validated for their potential to 
drive encephalitogenic properties of CNS infiltrating 
CTLs.
Nikola Wilck (Berlin) reported on his observations 
regarding dietary short chain fatty acids on the cardio-
vascular system. He proposed the hypothesis that propi-
onate ameliorated Angiotensin II driven cardiac damage 
and he provided evidence that dietary treatment with 
propionate had an immune mediated effect on the heart 
muscle by altering the balance of pro- vs anti-inflamma-
tory T cell subsets. It remains to be determined which 
molecular pathway (including G-protein coupled recep-
tor 41, 43, 109A or modulation of histone deacetylase) is 
used by propionate to exert its effects on immune cells.
Kavi Devraj (Frankfurt) introduced his in vitro system 
to measure effects of S1P modulators on endothelial cells 
in the context of the blood brain barrier. In mouse brain 
endothelial cells (MBEC), he could show that S1P1 block-
ers have a biphasic effect on the trans-endothelial resist-
ance: An early tightening and a late opening effect. The 
late effect of S1P1 modulators appeared to be mediated 
by VE-cadherin.
Anna Hammer (Erlangen) introduced the role of the 
receptor Mas in neuroinflammation. Mas is a G-protein 
coupled receptor of angiotensin (Ang)1–7 which can be 
generated from Ang II by the action of Ang converting 
enzyme 2. Ang1–7 binds Mas and induces vasodilatation. 
Since intervention in the renin/angiotensin axis has been 
shown to be beneficial in neuroinflammation, Hammer 
and colleagues decided to test the role of Mas in EAE. 
Mas−/− mice develop a more severe EAE as compared 
to littermate controls. Since Mas is expressed on mac-
rophages, the authors focused on the role of Ang1–7 in 
macrophage differentiation and—based on expression 
profiling of wild type vs Mas knock-out macrophages—
proposed the hypothesis that Mas mediated effects rather 
promote a M2 differentiation of macrophages.
Stefanie Kürten (Würzburg) showed her study on the 
role of Carcinoembryonic antigen-related cell adhesion 
molecule (CEACAM) 1 on B cells during chronic auto-
immune neuroinflammation. In a model of EAE induced 
with an MBP-PLP fusion protein (MP4), tertiary lym-
phoid aggregates emerge in the meningeal space and it 
has been proposed that the presence of these aggregates 
is associated with a progressive disease course in this 
model. Since CEACAM 1 was identified to be expressed 
on B cells, a depleting anti-CEACAM 1 antibody was 
tested to interfere with the clinical course in this model. 
In fact, anti-CEACAM 1 treatment reduced the num-
ber of newly formed tertiary lymphoid aggregates in the 
cerebellar parenchyma without affecting the peripheral 
B and T cell responses. Chronic disease symptoms were 
reduced by anti-CEACAM 1 treatment. Notably, MS 
patients harbor an increased fraction of CEACAM 1+ 
B cells in their circulating pool of naive B cells, mem-
ory B cells and B1 cells. Finally, in histologic specimens 
of SPMS patients CEACAM 1+ cells can be identified 
within meningeal aggregates of immune cells suggesting 
that anti-CEACAM 1 treatment might represent a means 
to interfere with the formation of B cell aggregates in MS 
patients as well.
Sabine Pfeifenbring (Göttingen) investigated axonal 
degeneration in children with MS to figure out quantita-
tive differences in axonal damage between pediatric and 
adult MS patients which might explain the clinical spe-
cificities of pediatric MS. Early MS lesions from pediatric 
patients were characterized according to demyelinating 
activity and presence of remyelination. Axonal damage 
was assessed using Bielschowsky’s silver impregnation 
and immunohistochemistry for amyloid precursor pro-
tein (APP). Biopsy and autopsy tissue from 19 children 
with MS were compared with 12 adult MS patients. 
Acute axonal damage was more extensive in children 
compared to adults. The highest extent of acute axonal 
damage was detectable in early active lesions of prepu-
bertal patients, while this group of patients also revealed 
the densest infiltration of macrophages/microglia within 
the lesions. The numbers of T lymphocytes did not sig-
nificantly differ between pediatric and adult MS patients. 
Furthermore, a higher EDSS at attack leading to biopsy 
or autopsy was associated with a higher extent of acute 
axonal damage. Hence, the extent of acute axonal damage 
seems to be one of the factors responsible for the often 
observed severe disease onset in pediatric MS.
Claudia Dames (Berlin) reported on her work on post 
stroke immunosuppression. After stroke, the parasym-
pathetic tone is increased. The relevance of this para-
sympathetic hyperactivity for immunosuppression was 
tested in a model of suboptimal bacterial pneumonia 
in post stroke mice. Vagotomy before stroke restored 
peripheral immunocompetence, while opposite effects 
were observed in nicotinic acetylcholine receptor α7 
knock-out mice. Interstitial SiglecF+F4/80+ (CD11c−) 
cells in the lung were significantly reduced during sev-
eral days post stroke. Stroke mice harbored increased 
levels of albumin in the bronchoalveolar lavage as a con-
sequence of loss of barrier function. In addition, stroke 
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mice had decreased muco-ciliary clearance and were—
perhaps also due to reduced numbers of interstitial mac-
rophages—incapable to clear a given bacterial burden. 
Sympathetic stimuli (nicotine) partly reversed post stroke 
immunosuppression.
Michael Bieber (Würzburg) presented data on stroke-
induced cardiac failure. Immediately after stroke, not 
only the parasympathetic but also the sympathetic tone is 
increased resulting in increased levels of catecholamines 
in the peripheral circulation. In humans, it has been 
reported that stroke affects the function of the heart. In 
a preclinical model of post-stroke hypersympathetic tone 
(at 8 weeks after stroke), myocardial fractional shorten-
ing and ejection fraction were decreased whereas brain 
natriuretic peptide expression as well as matrix metal-
lopeptidase 9 and TNF-α were increased in myocardial 
tissue. Interestingly, the cardiac phenotype post stroke 
was reversed by beta blockers. In parallel to ongoing 
mechanistic studies in this pre-clinical model, a large 
observational clinical trial was initiated to monitor heart 
affection after stroke.
Sarah Brockmann (Ulm) gave an overview on new 
genes linked to amyotrophic lateral sclerosis (ALS). 
While the fraction of ALS patients that can be tracked 
down to harbor genetic variants of either SOD or 
C9orf72 has increased over the past years, the discovery 
of novel mutations in ALS patients by exome sequencing 
will likely increase the fraction of genetically determined 
ALS even more in the future. CHCHD10 is a protein that 
is targeted to the crista junction in the membranes of 
mitochondria. It has been speculated that pathogenetic 
mutations of CHCHD10 interfered with the respiratory 
chain. However, more work is required as to which muta-
tions of CHCHD10 are really pathogenic and what their 
downstream targets are.
Fabian Szepanowski (Düsseldorf ) shared his data on 
the impact of fingolimod on peripheral nerve regenera-
tion. Sphingosine 1 phosphate receptor modulation was 
investigated in the sciatic nerve crush model in wild-type 
vs recombination-activating gene 1 knock-out (neither B 
nor T cells) vs forkhead box N1 knock-out (no T cells) 
mice. Fingolimod treatment was started 2  days before 
crush until 2  weeks after crush, and nerve conduction 
velocity was measured. It increased cyclic adenosine 
monophosphate levels in crushed nerves independently 
of the presence of T or B cells. Moreover, fingolimod 
inhibited lysophosphatidic acid synthesis and thereby 
improved remyelination with increased g-ratios in 
peripheral myelinated axons. Given these positive results 
it remains a speculation that the failure of fingolimod 
to exert neuroprotective properties in primary progres-
sive multiple sclerosis (INFORMS trial) might be due to 
the fact that the concentrations of fingolimod that were 
reached within the CNS were too low to be operational.
Ann-Kathrin Pulm (Düsseldorf–Münster) talked about 
her analysis of the role of endogenous interferon (IFN)
β during EAE. Using a reporter mouse for IFNβ (IRES-
YFP), it was shown that microglia were a relevant source 
of IFNβ at day 17 (peak of disease) in EAE. These acti-
vated microglia were identified as orchestrators of INFβ-
induced clearance of myelin debris.
Mathias Gelderblom (Hamburg) presented his analy-
sis of the role of dendritic cells (DC) in stroke. Dendritic 
cells are recruited early after stroke. Their infiltration 
peaked at day 3 and decreased by day 7 after stroke. The 
population composition of DCs changed during post 
stroke infiltration. While CD103−Sirp1a+ DCs dominate 
first and are then replaced by CD103+CD11b+XCR1+ 
DCs. Using the CD11c− diphteria toxin receptor mouse 
(CD11c.DOG) model, DCs were depleted before stroke, 
which led to smaller lesions. Notably, DC depleted mice 
had post stroke infiltrates with less gamma delta (γδ) T17 
cells and less neutrophils suggesting that DCs might acti-
vate γδT17 cells to license neutrophil infiltration post 
stroke. In fact, DCs are the main producers of IL-23 in 
the post stroke infiltrate and IL-23R knock-out mice 
recapitulated the phenotype of DC depleted mice in the 
stroke model.
Claudia Lange (Greifswald) gave an overview over the 
effects of stress hormones on circulating immune cells 
after stroke. Granulocytes collected from patients imme-
diately after an ischemic stroke showed an impaired 
oxidative burst after N-formyl-methionyl-leucyl-phe-
nylalanine stimulation and decreased necosis (area cov-
ered by DNA nets) after phorbol 12-myristate 13-acetate 
stimulation. These effects can be mimicked by incubation 
of granulocytes from healthy donors with noradrenaline 
while acetylcholine increases effector functions of granu-
locytes. Similarly, the cytotoxic activity of NK cells was 
reduced in response to stress hormones.
Karin Loser (Münster) reported on therapeutic 
approaches in neuroinflammation that exploit the ben-
eficial effect of UV light in EAE and MS. NDP-MSH is 
a more stable derivative of α-MSH (alpha-melanocyte 
stimulating hormone) that also is a more potent ago-
nist to the melanocortin1 receptor (MC1R). NDP-
MSH improved EAE be pleiotropic mechanisms. First, 
it expanded Foxp3+ Tregs. Second, it increased the 
laminin5 expression along the blood brain barrier to a 
continuous pattern and third, by up-regulating nuclear 
receptor subfamily 4 in neurons, NDP-MSH protected 
neurons from excitotoxicity. Interestingly, the immune 
mediated effects of NDP-MSH were recapitulated in the 
OSE mouse model of spontaneous EAE.
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Katharina Ochs (Heidelberg) presented a study on the 
co-incidence of MS and glial tumors. 23 patients with 
both diseases were identified. In 80 % of cases, MS pre-
ceded the onset of the tumor. All patients had a relaps-
ing MS course and the tumor entities were not biased 
towards a particular type of glioma (based on methyla-
tion epigenetics). The course of MS was likely not altered 
by the co-morbidity of the tumor although radiotherapy 
might be associated with increased relapse activity.
Christoph Harms (Berlin) presented novel data on 
the presence of an isoform of phosphatase and tensin 
homolog (PTEN; PTEN long) in neurons. Classic PTEN 
interferes with the phosphatidylinositide 3-kinase (PI3K) 
pathway by inhibiting the conversion of phosphatidylin-
ositol-bisphosphate to phosphatidylinositol trisphos-
phate. The new isoform PTEN long exists in neurons and 
also inhibits the PI3K/Akt pathway. Gain of function by 
transduction of PTEN classic or PTEN long into PTEN 
deficient neurons revealed that both isoforms appeared 
to be redundant, i.e. a loss of Akt phosphorylation was 
detected in both cases (WB on pAkt). In vitro, in the oxy-
gen and glucose deprivation model, PTEN deficient neu-
rons were rescued by both transduction of PTEN classic 
and PTEN long, again suggesting that both isoforms are 
redundant. Further experiments have to address whether 
PTEN long has a distinct function in neurons.
In conclusion, this year’s NEUROWIND meeting once 
again managed to be an exciting platform for bringing 
together highly motivated young scientists in experimen-
tal neurology to discuss scientific progress in the fields of 
neuroimmunology, vascular biology, and neurodegenera-
tion. All participants and the organizers are now looking 
forward to the upcoming NEUROWIND e.V. meeting in 
2016.
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